Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
Unterrainer M, Taugner J, Käsmann L, Tufman A, Reinmuth N, Li M, Mittlmeier LM, Bartenstein P, Kunz WG, Ricke J, Belka C, Eze C, Manapov F.
Unterrainer M, et al. Among authors: manapov f.
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1407-1416. doi: 10.1007/s00259-021-05584-w. Epub 2021 Oct 19.
Eur J Nucl Med Mol Imaging. 2022.
PMID: 34664091
Free PMC article.